PL1889067T3 - Aneksyna do oceny ryzyka wystąpienia raka - Google Patents

Aneksyna do oceny ryzyka wystąpienia raka

Info

Publication number
PL1889067T3
PL1889067T3 PL06743012T PL06743012T PL1889067T3 PL 1889067 T3 PL1889067 T3 PL 1889067T3 PL 06743012 T PL06743012 T PL 06743012T PL 06743012 T PL06743012 T PL 06743012T PL 1889067 T3 PL1889067 T3 PL 1889067T3
Authority
PL
Poland
Prior art keywords
annexin
risk assessment
cancer risk
tissue
urogenital
Prior art date
Application number
PL06743012T
Other languages
English (en)
Inventor
Michael Cahill
André Schrattenholz
Original Assignee
Proteosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05011042A external-priority patent/EP1724585A1/en
Application filed by Proteosys Ag filed Critical Proteosys Ag
Publication of PL1889067T3 publication Critical patent/PL1889067T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06743012T 2005-05-21 2006-05-22 Aneksyna do oceny ryzyka wystąpienia raka PL1889067T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05011042A EP1724585A1 (en) 2005-05-21 2005-05-21 Annexin for cancer risk assessment
EP05026092A EP1724586A3 (en) 2005-05-21 2005-11-30 Annexin for cancer risk assessment
PCT/EP2006/004818 WO2006125580A1 (en) 2005-05-21 2006-05-22 Annexin for cancer risk assessment
EP06743012A EP1889067B1 (en) 2005-05-21 2006-05-22 Annexin for cancer risk assessment

Publications (1)

Publication Number Publication Date
PL1889067T3 true PL1889067T3 (pl) 2011-10-31

Family

ID=36940167

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06743012T PL1889067T3 (pl) 2005-05-21 2006-05-22 Aneksyna do oceny ryzyka wystąpienia raka

Country Status (9)

Country Link
US (1) US8409812B2 (pl)
EP (2) EP1724586A3 (pl)
JP (1) JP2008545634A (pl)
KR (1) KR20080016809A (pl)
AT (1) ATE511653T1 (pl)
AU (1) AU2006251380B2 (pl)
CA (1) CA2608306A1 (pl)
PL (1) PL1889067T3 (pl)
WO (1) WO2006125580A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090023372A (ko) * 2006-06-09 2009-03-04 프로테오시스 악티엔게젤샤프트 전립선암의 검출을 위한 단일클론 항-아넥신 ａ3 항체
JP2008202978A (ja) * 2007-02-16 2008-09-04 Hirosaki Univ 前立腺癌の診断方法
MX2009010910A (es) * 2007-04-12 2010-01-20 Proteosys Ag Regulacion autoinmune de cancer de prostata por anexina a3.
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
JP5715817B2 (ja) 2007-07-19 2015-05-13 ビオメリューＢｉｏｍｅｒｉｅｕｘ 結腸直腸癌のインビトロ診断のための肝臓脂肪酸結合タンパク質、ｃｅａおよびｃａ１９−９のアッセイのための方法
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
EP2395357B1 (en) 2009-02-04 2015-05-06 Tokyo Institute of Technology Method for analyzing PSA, and method for distinguishing between prostate cancer and prostatomegaly employing the analysis method
JP5630757B2 (ja) 2009-10-30 2014-11-26 国立大学法人東京工業大学 Ｐｓａの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法
FR2968767B1 (fr) 2010-12-08 2012-12-21 Biomerieux Sa Procede et coffret pour le diagnostic in vitro du cancer de la prostate
WO2013076222A1 (en) 2011-11-23 2013-05-30 Proteosys Ag Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer
US9423402B2 (en) * 2011-11-30 2016-08-23 Singapore Health Services Pte. Ltd. GM1 ganglioside to annexin V microparticle polypeptide ratio for biological monitoring
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
FR2991777B1 (fr) 2012-06-07 2015-08-21 Biomerieux Sa Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives
WO2016031816A1 (ja) 2014-08-26 2016-03-03 学校法人慶應義塾 抗がん剤の感受性の判定マーカー
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
CN117018185A (zh) * 2022-03-18 2023-11-10 江苏靶标生物医药研究所有限公司 TNF-α纳米抗体与PGE2联用在制备溃疡性结肠炎药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511829B1 (en) 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
AU2001290518A1 (en) 2000-08-03 2002-02-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20040033502A1 (en) * 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
CZ20032787A3 (en) * 2001-04-03 2004-03-17 Merck Patent Gmbh Renal cell carcinoma tumor markers
WO2002080754A2 (en) 2001-04-03 2002-10-17 Theseus Imaging Corporation Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20040241653A1 (en) 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
AU2003201741A1 (en) * 2002-01-09 2003-07-24 Yusuke Nakamura Cancer profiles
DE10302422A1 (de) * 2003-01-21 2004-07-29 Responsif Gmbh Medikament und Verwendung zur Tumortherapie
EP2295976A1 (en) * 2003-03-08 2011-03-16 Auvation Ltd Markers for colorectal cancer
JP5068543B2 (ja) 2004-02-16 2012-11-07 プロテオジス アクチェンゲゼルシャフト がんに関する診断マーカー
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
KR20090023372A (ko) * 2006-06-09 2009-03-04 프로테오시스 악티엔게젤샤프트 전립선암의 검출을 위한 단일클론 항-아넥신 ａ3 항체

Also Published As

Publication number Publication date
ATE511653T1 (de) 2011-06-15
HK1118095A1 (en) 2009-01-30
EP1724586A2 (en) 2006-11-22
JP2008545634A (ja) 2008-12-18
AU2006251380B2 (en) 2011-05-19
WO2006125580A1 (en) 2006-11-30
AU2006251380A1 (en) 2006-11-30
US20100267051A1 (en) 2010-10-21
US8409812B2 (en) 2013-04-02
KR20080016809A (ko) 2008-02-22
CA2608306A1 (en) 2006-11-30
EP1889067A1 (en) 2008-02-20
EP1724586A3 (en) 2007-07-04
EP1889067B1 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
PL1889067T3 (pl) Aneksyna do oceny ryzyka wystąpienia raka
EP1842065A4 (en) METHODS OF DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2010056351A3 (en) Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2009055820A3 (en) Salivary protein biomarkers for human oral cancer
WO2011072177A3 (en) Biomarker assay for diagnosis and classification of cardiovascular disease
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
EP1846015A4 (en) METHOD, COMPOSITIONS AND CLASSIFICATION FOR TUMOR DIAGNOSIS AND TREATMENT
EP2674435A3 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2006121892A3 (en) Diagnosis of liver pathology through assessment of protein glycosylation
DE602007011566D1 (en) Ankheit
ATE424560T1 (de) Marker für neuromyelitis optica
WO2005098445A3 (en) Lung cancer biomarkers
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
WO2007030928A8 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
WO2007032876A3 (en) Biomarkers associated with age-related macular degeneration
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2008103202A3 (en) Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
WO2006138219A3 (en) Methods of diagnosis / prognosis of inflammatory conditions